TY - JOUR
T1 - Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy
AU - Jabbour, Elias
AU - Garcia-Manero, Guillermo
AU - Batty, Nicolas
AU - Shan, Jenny
AU - O'Brien, Susan
AU - Cortes, Jorge
AU - Ravandi, Farhad
AU - Issa, Jean Pierre
AU - Kantarjian, Hagop
PY - 2010/8/15
Y1 - 2010/8/15
N2 - BACKGROUND: The prognosis of patients with myelodysplastic syndrome (MDS) after decitabine failure is not known. METHODS: Data from 87 patients with MDS (n = 67) and chronic myelomonocytic leukemia (n = .20) after failure of decitabine regimens were reviewed. RESULTS: After a median follow-up of 21 months from decitabine failure, 13 (15%) patients remained alive; the median survival was 4.3 months, and the estimated 12-month survival rate was 28%. The estimated 12-month survival rates were 27%, 33%, and 33%, respectively, for patients with high-risk, intermediate-2-risk, and intermediate-1-risk disease (P = .99) by the International Prognostic Scoring System. The estimated 12-month survival rates were 100%, 54%, 41%, and 18%, respectively, for patients with low-risk, intermediate-1-risk, intermediate-2-risk, and high-risk disease according to The University of Texas M. D. Anderson Cancer Center risk model (P = .01). CONCLUSIONS: The outcome of patients after decitabine failure is poor and appears to be predictable after decitabine failure.
AB - BACKGROUND: The prognosis of patients with myelodysplastic syndrome (MDS) after decitabine failure is not known. METHODS: Data from 87 patients with MDS (n = 67) and chronic myelomonocytic leukemia (n = .20) after failure of decitabine regimens were reviewed. RESULTS: After a median follow-up of 21 months from decitabine failure, 13 (15%) patients remained alive; the median survival was 4.3 months, and the estimated 12-month survival rate was 28%. The estimated 12-month survival rates were 27%, 33%, and 33%, respectively, for patients with high-risk, intermediate-2-risk, and intermediate-1-risk disease (P = .99) by the International Prognostic Scoring System. The estimated 12-month survival rates were 100%, 54%, 41%, and 18%, respectively, for patients with low-risk, intermediate-1-risk, intermediate-2-risk, and high-risk disease according to The University of Texas M. D. Anderson Cancer Center risk model (P = .01). CONCLUSIONS: The outcome of patients after decitabine failure is poor and appears to be predictable after decitabine failure.
KW - Decitabine
KW - Failure
KW - Myelodysplastic syndrome
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=77956862198&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956862198&partnerID=8YFLogxK
U2 - 10.1002/cncr.25247
DO - 10.1002/cncr.25247
M3 - Article
C2 - 20564137
AN - SCOPUS:77956862198
SN - 0008-543X
VL - 116
SP - 3830
EP - 3834
JO - Cancer
JF - Cancer
IS - 16
ER -